Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
KC Kähler, JC Hassel, L Heinzerling… - JDDG: Journal der …, 2016 - Wiley Online Library
Summary CTLA‐4 and PD‐1 are potential targets for tumor‐induced downregulation of
lymphocytic immune responses. Immune checkpoint‐modifying monoclonal antibodies …
lymphocytic immune responses. Immune checkpoint‐modifying monoclonal antibodies …
Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
KC Kähler, JC Hassel, L Heinzerling, C Loquai… - JDDG: Journal der …, 2016 - cir.nii.ac.jp
抄録< jats: title> Summary</jats: title>< jats: p> CTLA‐4 and PD‐1 are potential targets for
tumor‐induced downregulation of lymphocytic immune responses. Immune checkpoint …
tumor‐induced downregulation of lymphocytic immune responses. Immune checkpoint …
Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
KC Kähler, JC Hassel, L Heinzerling, C Loquai… - JDDG: Journal der …, 2016 - infona.pl
CTLA‐4 and PD‐1 are potential targets for tumor‐induced downregulation of lymphocytic
immune responses. Immune checkpoint‐modifying monoclonal antibodies oppose these …
immune responses. Immune checkpoint‐modifying monoclonal antibodies oppose these …
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
KC Kaehler, JC Hassel, L Heinzerling, C Loquai… - 2016 - publications.goettingen-research …
CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic
immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these …
immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these …
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
KC Kähler, JC Hassel, L Heinzerling… - … = Journal of the …, 2016 - pubmed.ncbi.nlm.nih.gov
CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic
immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these …
immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these …
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.
KC Kähler, JC Hassel, L Heinzerling… - … = Journal of the …, 2016 - europepmc.org
CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic
immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these …
immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these …